Tag Archive: Martin Shkreli


“Invariably, when people read the headline about Martin Shkreli, they hate Martin Shkreli. When they get to know Martin Shkreli, they love Martin Shkreli.” – Martin Shkreli on Twitter

“He (Shkreli) needs to be mythical. He needs to be larger than life. He needs to be a rags-to-riches story. That image is his mansion. His Maserati.” – Assistant U.S. Attorney Jacquelyn Kasulis

Martin Shkreli will be celebrating his 35th birthday next Saturday … behind bars.

Earlier, he labeled his federal prosecutors as the “junior varsity.” The JV team won.

His final destination will not be “Club Fed” as Shkreli once boasted on Twitter.

The sentence is seven years in prison with credit for the six months already served, and a $7.4 million fine.

Last month, CNBC dedicated its season debut of “American Greed” to Martin Shkreli. It was a personal branding and reputation management horror show, plain and simple.

There are zero public relations pros — regardless of their years of experience and skill – who could have saved Martin Shkreli from … himself.

No one loves Martin Shkreli – maybe with the exception of Martin Shkreli.

Among his litany of sins – the always smirking, taunting, arrogant Martin Shkreli — violated the cardinal rule of public relations (as if he ever weighed his own PR):

The most important public relations of all … is personal PR.

Former hedge-fund Wunderkind/drug-price fixer Shkreli received a seven year sentence for three counts of securities fraud.

 

His attorneys fought against a full 15-year sentence recommended by the U.S. Attorney, arguing he reportedly should not receive the maximum simply because he is … Martin Shkreli.

Shkreli long ago lost in the courtrooms of public opinion, where he was convicted for being … as the Brits would say, an arse.

For some reason, he refused to even acknowledge the myriad of societal stop signs, which constrain mere mortals. Even on Capitol Hill when he was taking the 5th (Amendment), he was even taunting Members of Congress with his characteristic smirk, and later insulted them on social media.

And today there is a worldwide breakout of Schadenfreude. We are all happy, including Almost DailyBrett, that Martin Shkreli is so sad.

Bringing The Donald and Hillary Together

“That guy is nothing. He’s zero. He’s nothing. He ought to be ashamed of himself.” – Donald Trump

“He still hasn’t said how much the drug will cost going forward, and in the meantime, sick patients still have to wait and worry and continue to pay $750/pill. So Mr. Shkreli, what’s it going to be?” – Hillary Clinton

“If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don’t think that that should be a crime.” – Martin Shkreli on raising the price of Daraprim by 5,000 percent

Martin Shkreli performed magic during the divisive 2016 presidential campaign; he managed to bring Donald Trump and Hillary Clinton into an one-time agreement.

He defrauded his MSMB Capital investors, and raised the price of AIDS drug, Daraprim, from $13.50 to $750 per pill.

With his indefensible actions Shkreli also indicted the entire American pharmaceutical industry, leaving the impression that every company was gauging patients with unjustifiable drug price increases. Some are guilty. Some are innocent.

Eventually, Shkreli called upon his social media followers to steal a lock of Hillary Clinton’s hair as a bounty. He subsequently lost his $5 million bail, and was remanded to jail in Brooklyn.

Shkreli’s attorneys were hoping for a 12-18 month sentence. Federal prosecutors were asking for 15 years or even more. The judge played the sentence right down the middle: seven years.

The reality of jail and the prospect of more than one decade in prison seemed to make an overdue impression on Shkreli.

“There is no conspiracy to take down Martin Shkreli. I took down Martin Shkreli, with my disgraceful and shameful actions … This is my fault. I am not a victim here.” – Martin Shkreli at his March 9 sentencing.

Did Shkreli finally listen to his lawyers?

Was his statement before the judge, and by extension the world, written by a public relations counselor?

Did he in the end, get religion?

Too little, too late Martin.

https://www.cnbc.com/2018/03/09/pharma-bro-martin-shkreli-sentenced-to-7-years-in-prison.html

https://www.wsj.com/articles/martin-shkreli-sentenced-to-seven-years-in-prison-1520621915

https://www.cnbc.com/2018/02/23/the-american-greed-report-how-to-beat-the-pharma-bros-and-save-money-on-your-prescriptions.html

https://www.wsj.com/articles/martin-shkreli-found-guilty-in-securities-fraud-trial-1501873444?mod=searchresults&page=1&pos=35

https://www.hollywoodreporter.com/news/donald-trump-blasts-martin-shkreli-826848

https://en.wikipedia.org/wiki/Martin_Shkreli

 

“This is a dangerous moment for the life sciences industry that is increasingly vital to the U.S. economy.” — Lead Wall Street Journal editorial, Sept. 23, 2015

There are dirty-little secrets out there …

If one buys low and sells high, there is a resulting profit.

If demand is high and supply is low, prices rise … profits are likely.

And some forward-looking companies may take those profits and plow them right back into R&D (research and development), resulting technological breakthroughs may ensue, which may lead to more profits … and more R&D. Sounds like a plan to Almost DailyBrett.biotech

There are some who just don’t agree with buy low, sell high. There are some who are not enamored with supply and demand. In fact, they are declaring war on capitalistic “profiteering.”

The target du jour is bio-technology, the very folks who produce cures (e.g., Hepatitis C) and management regimes to control diseases (e.g., AIDS). One would think these biotech superstars, such as Gilead Sciences (NASDAQ: GILD), would be regarded as heroes. Alas, you would be wrong.

Certainly, there is a poster-child villain in this story.shkreli

His name is Martin Shkreli, the chief executive officer of Turing Pharmaceuticals, guilty of raising the price of parasite infection drug, Daraprim, by 4,000 percent. The 32-year-young hedge-fund manager beat a hasty retreat last week in the face of a chorus of cat calls. He is a walking-talking, first-rate public relations disaster.

Having made this point, should the entire life sciences industry, its scientists and patients, some in desperate need of breakthrough drugs, be punished for the sins of a hedge-fund manager and presumably a few others?

Here are a few more troubling price-control questions:

  • Will after-tax R&D expenditures of life sciences and by natural extension, technology companies, become the subject of regulatory-imposed quotas (e.g., no more than x percent of net income can be used for R&D)?
  • What impacts will these Washington D.C., or Sacramento-initiated command-and-control limitations have on finding cures for diseases or next generation killer apps? Will there be fewer newer drugs on the market? Will there be less “destructive” game-changing technologies?
  • Will other operating expenses on the income statement also be subject to governmental expenditure controls, such as SG&A (selling, general and administrative)? For example, will life sciences, software and/or hardware companies be restricted in how much they can spend to market a breakthrough product? What impacts will these restrictions, if they become reality, have on the fiscal health public relations and advertising agencies?
  • What happens to heart disease, cancer, Alzheimer’s patients and others facing potentially fatal diseases, if the political class imposes draconian controls on new drug development … pharmaceuticals that potentially could save their lives?

Guess life’s tough, right?

Steve Jobs Turning Over in His Grave?jobsmemorial

There are ballot initiatives circulating in California – the home of Silicon Valley technology and some big league life sciences companies – that would impose price controls on pharmaceuticals and limitations on after tax R&D, marketing and presumably other operating expenditures.

Do you think that once emboldened the political elites will stop at the income statements of life sciences companies? Or would they march onto the next battle: social, mobile and cloud companies in Silicon Valley and San Francisco?

Let’s see, the price for an Apple 6s smart phone is $849.99. There are no deals or discounts on Apple smart phones. Is that price too high? Are we all entitled to have a smart phone? Should price controls be imposed on Apple smart phones, tablets, watches, Macs, iPods …?

Whattyathink Tim Cook?

Looking at the income statement for Q3, Apple generated $49.6 billion on the top line (Is that too much?).

The company paid $3.79 billion in taxes (Is that too little?).

Apple devoted $2.03 billion for R&D and $3.56 billion for SG&A (Are these figures simply way too much for research and marketing respectively?).

The company also devoted $29.9 billion for COGS or the cost to make its breakthrough products. (Does Apple really need to spend that much? Your collectivist thoughts, Sacramento and/or Washington?)

Worse yet, Apple produced a profit of $10.67 billion. Is the company (and many others) guilty of “profiteering.”

These figures are reflections of not only extraordinary success, but engineering breakthroughs, entrepreneurial spirit, calculated gambles of consumer acceptance, and of course, the risk of failure.

The whole notion of venture capital is to spend private equity on ideas that may stick to the wall, but then they may also flop. An idea may be good, but too early for consumer acceptance (e.g., HDTV in the 1990s).

77979722-87e3-430f-b0a1-29933dfa2782

One of the distinguishing characteristics of America, which makes it the land of opportunity, is calculated risk-taking of entrepreneurs. Ultimately, they have the super ideas that may lead to landmark products and with them literally tens of thousands of new jobs – not family wage jobs (whatever they are), but career path jobs.

Should we literally kill the goose that is laying golden eggs?

http://www.wsj.com/articles/the-assault-on-drug-innovation-1442964103

http://www.wsj.com/articles/the-biotech-rout-1443484644

http://www.wsj.com/articles/hillary-vs-cancer-treatment-1443007218

https://gma.yahoo.com/company-lower-drug-price-critics-called-4-000-002025809–abc-news-health.html#

http://www.apple.com/pr/library/2015/07/21Apple-Reports-Record-Third-Quarter-Results.html

 

 

 

 

 

%d bloggers like this: